Kit - KIT proto-oncogene receptor tyrosine kinase Gene

中文名称：K IT 原癌基因受体酪氨酸激酶

种属: Mus musculus

同用名: W; Bs; Fdc; Ssm; SCO1; SCO5; SOW3; CD117; c-KIT; Tr-kit; Gsfsco1; Gsfsco5; Gsfsow3

基因 ID: 16590 | 基因类型: protein coding

关于 Kit

Chromosome 5: 75,735,576-75,817,382 forward strand.GRCm39:CM000998.3

This gene has 8 transcripts (splice variants), 206 orthologues, 53 paralogues and is associated with 222 phenotypes. Broad expression in lung adult (RPKM 39.), cerebellum adult (RPKM 19.6) and 25 other tissues.

功能概要

c-Kit 原癌基因是猫逆转录病毒 (v-Kit) 转化基因的细胞同系物。 c-Kit 蛋白包括蛋白激酶跨膜受体的特征。已发现该基因编码不同亚型的可变剪接转录物变体。 [RefSeq 提供，2008 年 7 月]

The c-Kit proto-oncogene is the cellular homolog of the transforming gene of a feline retrovirus (v-Kit). The c-Kit protein includes characteristics of a protein kinase transmembrane receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Kit 基因产物(2)

mRNA	Protein	Name
NM_001122733.1	NP_001116205.1	mast/stem cell growth factor receptor Kit isoform 1 precursor
NM_021099.3	NP_066922.2	mast/stem cell growth factor receptor Kit isoform 2 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables SH2 domain binding	IPI IPI: 通过物理相互作用推断	14612394	MGI
enables protease binding	IPI IPI: 通过物理相互作用推断	12135759	MGI
enables protein binding	IPI IPI: 通过物理相互作用推断	1698557	MGI
enables stem cell factor receptor activity	IDA IDA: 通过直接分析推断	10872802	MGI

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in T cell differentiation	IMP IMP: 通过突变表型推断	12354381	MGI
acts upstream of cell population proliferation	IGI IGI: 通过遗传相互作用推断	10620616	MGI
acts upstream of or within cytokine-mediated signaling pathway	IDA IDA: 通过直接分析推断	10872802	MGI
involved in detection of mechanical stimulus involved in sensory perception of sound	IMP IMP: 通过突变表型推断	15731517	MGI
acts upstream of or within developmental pigmentation	IGI IGI: 通过遗传相互作用推断	18454205	MGI
acts upstream of or within developmental pigmentation	IMP IMP: 通过突变表型推断	15322542	MGI
involved in digestive tract development	IMP IMP: 通过突变表型推断	15067126	MGI
acts upstream of or within ectopic germ cell programmed cell death	IGI IGI: 通过遗传相互作用推断	14660547	MGI
acts upstream of ectopic germ cell programmed cell death	IMP IMP: 通过突变表型推断	18308723	MGI
involved in embryonic hemopoiesis	IMP IMP: 通过突变表型推断	20536544	MGI
involved in erythrocyte differentiation	IMP IMP: 通过突变表型推断	12354381	MGI
involved in erythropoietin-mediated signaling pathway	IMP IMP: 通过突变表型推断	18538998	MGI
acts upstream of or within glycosphingolipid metabolic process	IMP IMP: 通过突变表型推断	18308723	MGI
acts upstream of or within hematopoietic stem cell migration	IMP IMP: 通过突变表型推断	20847314	MGI
acts upstream of or within hemopoiesis	IMP IMP: 通过突变表型推断	11805142	MGI
involved in immature B cell differentiation	IMP IMP: 通过突变表型推断	15067126	MGI
involved in inflammatory response	IMP IMP: 通过突变表型推断	18454155	MGI
acts upstream of or within intracellular signal transduction	IDA IDA: 通过直接分析推断	10872802	MGI
involved in lamellipodium assembly	IDA IDA: 通过直接分析推断	10982396	MGI
acts upstream of or within lymphoid progenitor cell differentiation	IGI IGI: 通过遗传相互作用推断	7621074	MGI
acts upstream of or within mast cell differentiation	IMP IMP: 通过突变表型推断	18258601	MGI
involved in mast cell differentiation	IMP IMP: 通过突变表型推断	15067126	MGI
acts upstream of mast cell proliferation	IGI IGI: 通过遗传相互作用推断	10620616	MGI
involved in megakaryocyte development	IMP IMP: 通过突变表型推断	15067126	MGI
involved in melanocyte adhesion	IDA IDA: 通过直接分析推断	22637532	MGI
involved in melanocyte differentiation	IMP IMP: 通过突变表型推断	15768389	MGI
involved in melanocyte migration	IMP IMP: 通过突变表型推断	15067126	MGI
acts upstream of or within myeloid progenitor cell differentiation	IGI IGI: 通过遗传相互作用推断	7621074	MGI
acts upstream of or within negative regulation of developmental process	IMP IMP: 通过突变表型推断	18308723	MGI
acts upstream of or within negative regulation of programmed cell death	IGI IGI: 通过遗传相互作用推断	14660547	MGI
acts upstream of or within negative regulation of programmed cell death	IMP IMP: 通过突变表型推断	18308723	MGI
acts upstream of or within negative regulation of reproductive process	IMP IMP: 通过突变表型推断	18308723	MGI
involved in ovarian follicle development	IMP IMP: 通过突变表型推断	20536544	MGI
acts upstream of or within peptidyl-tyrosine phosphorylation	IDA IDA: 通过直接分析推断	10872802	MGI
acts upstream of or within pigmentation	IGI IGI: 通过遗传相互作用推断	10620616	MGI
involved in pigmentation	IMP IMP: 通过突变表型推断	15067126	MGI
acts upstream of or within positive regulation of MAP kinase activity	IGI IGI: 通过遗传相互作用推断	10620616	MGI
involved in positive regulation of dendritic cell cytokine production	IMP IMP: 通过突变表型推断	18454155	MGI
acts upstream of or within positive regulation of gene expression	IMP IMP: 通过突变表型推断	18308723	MGI
acts upstream of or within positive regulation of mast cell proliferation	IGI IGI: 通过遗传相互作用推断	10620616	MGI
acts upstream of programmed cell death	IGI IGI: 通过遗传相互作用推断	14660547	MGI
acts upstream of or within protein phosphorylation	IDA IDA: 通过直接分析推断	11805142	MGI
involved in regulation of cell shape	IDA IDA: 通过直接分析推断	10982396	MGI
acts upstream of or within response to radiation	IMP IMP: 通过突变表型推断	12833143	MGI
acts upstream of or within spermatid development	IMP IMP: 通过突变表型推断	18308723	MGI
involved in spermatogenesis	IMP IMP: 通过突变表型推断	20536544	MGI
involved in stem cell differentiation	IMP IMP: 通过突变表型推断	18258857	MGI

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cell surface	IDA IDA: 通过直接分析推断	9216738	MGI
located in cell-cell junction	IDA IDA: 通过直接分析推断	23284756	MGI
located in external side of plasma membrane	IDA IDA: 通过直接分析推断	10943842	MGI

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Kit 蛋白结构

IgI_4_SCFR

PTKc_Kit

0
200
400
600
800
979 a.a.

蛋白主名

其他名称

mast/stem cell growth factor receptor Kit

Dominant white spotting	SCFR
Steel Factor Receptor	belly-spot
c-kit proto-oncogene protein	dominant spotting
kit oncogene	proto-oncogene c-Kit
proto-oncogene tyrosine-protein kinase Kit	spotted sterile male
tyrosine-protein kinase Kit

重组 Kit 蛋白

目录号	产品名	蛋白编号	纯度
HY-P72879	CD117/c-Kit Protein, Mouse (HEK293, Fc)	P05532 (S25-T523)	≥95%
HY-P72880	CD117/c-Kit Protein, Mouse (HEK293, His)	P05532 (S25-T523)	≥95%
HY-P78712	CD117/c-kit Protein, Mouse (495a.a, HEK293, Fc)	P05532-2 (S25-T519)	≥95%

相关产品

Approval

生物活性分子 (28)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10201	Sorafenib		99.92%	是
HY-10981	Lenvatinib	Inhibitor	99.75%	是
HY-16749	Pexidartinib		99.64%	是
HY-10331	Regorafenib		99.93%	是
HY-15463	Imatinib		99.95%	是
HY-13016	Cabozantinib		99.96%	是
HY-10230	Midostaurin		99.91%	是
HY-10208	Pazopanib		99.91%	是
HY-50946	Imatinib Mesylate		99.98%	是
HY-10201A	Sorafenib Tosylate		99.91%	是
HY-101561	Avapritinib	Inhibitor	99.94%	是
HY-10981A	Lenvatinib mesylate	Inhibitor	99.86%	是
HY-112306	Ripretinib		98.90%	是
HY-10209	Masitinib		99.98%	是
HY-16749A	Pexidartinib hydrochloride		99.86%	是
HY-12009	Pazopanib Hydrochloride		99.99%	是
HY-12044	Cabozantinib S-malate		99.90%	是
HY-10331A	Regorafenib monohydrate		99.96%	是
HY-13308	Regorafenib Hydrochloride		99.58%	是
HY-13904	Flumatinib	Inhibitor	99.94%	否
HY-10209A	Masitinib mesylate		99.83%	是
HY-13311A	Infigratinib phosphate	Inhibitor	99.74%	是
HY-10330	Toceranib	Inhibitor	96.86%	否
HY-10330A	Toceranib phosphate	Inhibitor	98.54%	否
HY-10201R	Sorafenib (Standard)		/	否
HY-10331B	Regorafenib mesylate		/	否
HY-13016A	Cabozantinib hydrochloride		/	否
HY-50946R	Imatinib Mesylate (Standard)		/	否

Clinical Phase

生物活性分子 (29)

目录号	产品名	作用方式	纯度	Phase
HY-13905	Flumatinib mesylate	Inhibitor	99.87%	Phase 4
HY-16961	Sitravatinib	Inhibitor	99.57%	Phase 3
HY-50905	Dovitinib	Inhibitor	99.88%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-145557	Bezuclastinib	Inhibitor	98.59%	Phase 3
HY-10228	Motesanib	Inhibitor	99.96%	Phase 3
HY-136256	Vimseltinib	Inhibitor	99.08%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-108713	Famitinib		98.43%	Phase 3
HY-124526	Chiauranib	Inhibitor	99.28%	Phase 3
HY-152839	Elenestinib	Inhibitor	98.82%	Phase 3
HY-10229	Motesanib Diphosphate	Inhibitor	99.64%	Phase 3
HY-10207	Dovitinib lactate	Inhibitor	99.75%	Phase 3
HY-16961A	Sitravatinib malate	Inhibitor	/	Phase 3
HY-B0062	Dovitinib lactate hydrate	Inhibitor	/	Phase 3
HY-108713A	Famitinib malate		/	Phase 3
HY-13024	Rebastinib		99.91%	Phase 2
HY-109086	Edicotinib	Inhibitor	98.78%	Phase 2
HY-10206	Amuvatinib		99.47%	Phase 2
HY-10527	Telatinib	Inhibitor	99.60%	Phase 2
HY-10202	Tandutinib		99.48%	Phase 2
HY-109190	Seralutinib	Inhibitor	99.94%	Phase 2
HY-10202A	Tandutinib hydrochloride		99.78%	Phase 2
HY-10527C	Telatinib mesylate	Inhibitor	99.74%	Phase 2
HY-10206A	Amuvatinib hydrochloride	Inhibitor	/	Phase 2
HY-10204	OSI-930		98.57%	Phase 1
HY-12010	BMS-599626 Hydrochloride	Inhibitor	99.68%	Phase 1
HY-B1684	Mebrofenin		99.88%	Phase 1
HY-10251	BMS-599626	Inhibitor	/	Phase 1

抗体抑制剂 (1)

目录号	产品名	作用方式	纯度	Phase
HY-P99462	Barzolvolimab	Inhibitor	99.83%	Phase 2

Pre-clinical Phase

生物活性分子 (98)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-10514	BX795		99.84%	否
HY-10501	SU14813	Inhibitor	99.63%	否
HY-131339	SP-96	Inhibitor	99.42%	否
HY-10873	N-Desethyl Sunitinib		99.90%	否
HY-101443	ISCK03	Inhibitor	99.50%	否
HY-13894	Tyrphostin AG1296		99.69%	否
HY-132166	M4205	Inhibitor	99.47%	否
HY-112802	AZD3229	Inhibitor	99.69%	否
HY-13838	PLX647	Inhibitor	99.79%	否
HY-G0017	N-Desmethyl imatinib		99.16%	否
HY-10408	Ki20227	Inhibitor	99.17%	否
HY-I0678	Regorafénib N-oxyde (M2)		99.32%	否
HY-15240	c-Kit-IN-1	Inhibitor	98.83%	否
HY-10501A	SU14813 maleate	Inhibitor	99.04%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-112452	SU11652		99.06%	否
HY-103274	PD180970		99.27%	否
HY-15813	FIIN-1	Inhibitor	99.11%	否
HY-13016S	Cabozantinib-d6		98.14%	否
HY-160765	WNTinib		99.95%	否
HY-18302	c-Kit-IN-5-1	Inhibitor	98.16%	否
HY-13493	AC710	Inhibitor	98.56%	否
HY-112616	NAMPT inhibitor-linker 2	Inhibitor	98.11%	否
HY-103032	Multi-kinase inhibitor 1	Inhibitor	99.34%	否
HY-15463S	Imatinib-d8		99.85%	否
HY-15463S1	Imatinib-d4		99.97%	否
HY-18179	AZD2932	Inhibitor	99.04%	否
HY-W143698	PDGFRα kinase inhibitor 2	Inhibitor	≥98.0%	否
HY-112615	NAMPT inhibitor-linker 1		98.08%	否
HY-10981S	Lenvatinib-d4	Inhibitor	99.59%	否
HY-133980A	O-Demethyl Lenvatinib hydrochloride		95.54%	否
HY-136201	Sodium Glucoheptonate		≥98.0%	否
HY-138813	N-Desethyl Sunitinib hydrochloride		99.77%	否
HY-112802A	AZD3229 Tosylate	Inhibitor	99.80%	否
HY-10208S	Pazopanib-d6		≥98.0%	否
HY-10230S	Midostaurin-d5	Inhibitor	≥98.0%	否
HY-10331S	Regorafenib-d3		≥98.0%	否
HY-110293	CHMFL-FLT3-122		98.47%	否
HY-12009S	Pazopanib-13C,d3 hydrochloride		97.51%	否
HY-123450	S116836		99.65%	否
HY-13342AS	Apatinib-d8 free base		92.56%	否
HY-133980	O-Demethyl Lenvatinib		/	否
HY-15198	KG5	Inhibitor	99.79%	否
HY-15463S2	Imatinib-d3 hydrochloride		95.19%	否
HY-156619	Labuxtinib	Inhibitor	99.76%	否
HY-15814	HG-7-85-01		99.94%	否
HY-18317	JNJ-38158471	Inhibitor	97.02%	否
HY-101034	CHMFL-ABL/KIT-155		/	否
HY-128589	CHMFL-KIT-033	Inhibitor	/	否
HY-128602	c-Kit-IN-2	Inhibitor	/	否
HY-10873S	N-Desethyl Sunitinib-d5		/	否
HY-10201S2	Sorafenib-13C,d3		98.35%	否
HY-10208S1	Pazopanib-13C,d3		/	否
HY-10331S1	Regorafenib-13C,d3		/	否
HY-10638	AP23464		/	否
HY-109086A	Edicotinib hydrochloride	Inhibitor	/	否
HY-10981S1	Lenvatinib-d5	Inhibitor	/	否
HY-10981S2	Lenvatinib-15N,d4	Inhibitor	/	否
HY-110071	APcK110	Inhibitor	/	否
HY-110272	Vatalanib succinate	Inhibitor	/	否
HY-117873	KBP-7018	Inhibitor	/	否
HY-117873A	KBP-7018 hydrochloride	Inhibitor	/	否
HY-121708	KI-328		/	否
HY-121874	EP009	Inhibitor	/	否
HY-13016S1	Cabozantinib-d4		/	否
HY-131275	Imatinib Impurity E		96.05%	否
HY-132451S	(R,S)-4-Hydroxy Cyclophosphamide-d4 Preparation Kit		/	否
HY-13645	Henatinib	Inhibitor	/	否
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	否
HY-13904S	Flumatinib-d3	Inhibitor	/	否
HY-139996	Pomalidomide-C5-Dovitinib		/	否
HY-143894	FLT3-IN-11	Inhibitor	/	否
HY-143895	FLT3-IN-12	Inhibitor	/	否
HY-147864	c-Fms-IN-12		/	否
HY-149019	Antitumor agent-70		/	否
HY-149415	Multi-kinase-IN-5	Inhibitor	/	否
HY-150026	Multi-kinase-IN-2		/	否
HY-156470	Multi-kinase-IN-6		/	否
HY-160689	GW694590A	Inhibitor	/	否
HY-168579	c-Kit-IN-6	Inhibitor	/	否
HY-168580	c-Kit-IN-7	Inhibitor	/	否
HY-168581	c-Kit-IN-8	Inhibitor	/	否
HY-18949	JI6	Inhibitor	/	否
HY-50905S	Dovitinib-d8	Inhibitor	/	否
HY-G0017A	N-Desmethyl imatinib mesylate		/	否
HY-G0017S1	N-Desmethyl imatinib-d4		/	否
HY-I0678S	Regorafénib N-oxyde-d3 (M2)		/	否
HY-I0678S1	Regorafénib N-oxyde (M2)-13C,d3		/	否
HY-RS07319	KIT Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07320	Kit Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07321	Kit Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-10330S	Toceranib-d8	Inhibitor	/	否
HY-10873S2	N-Desethyl Sunitinib-d5 hydrochloride		/	否
HY-112350	AGL 2043	Inhibitor	/	否
HY-116116	Tafetinib	Inhibitor	/	否
HY-13493A	AC710 Mesylate	Inhibitor	/	否
HY-18187	Ki 23057	Inducer	/	否
HY-111947	c-Fms-IN-6	Inhibitor	/	否

抗体抑制剂 (1)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-P990002	Anti-Mouse CD117/c-Kit Antibody (2B8)	Inhibitor	≥95.0%	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Kit	NCBI	NCBI:3815
Canis familiaris	Kit	NCBI	NCBI:403811
Rattus norvegicus	Kit	NCBI	NCBI:64030
Macaca mulatta	Kit	NCBI	NCBI:696759

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4